Is Plant Sterols Cholesterol Meta-Analysis safe?

Updated October 2026

Quick Answer

Plant Sterols Cholesterol Meta-Analysis has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Evidence from published experimental, clinical, and mechanistic investigations that were indexed in PubMed, Scopus, Web of Science, and Google Scholar between 2014 and 2025 is compiled in this review.

Key Takeaways

  • 01Evidence from published experimental, clinical, and mechanistic investigations that were indexed in PubMed, Scopus, Web of Science, and Google Scholar between 2014 and 2025 is compiled in this review. [Alatawi K (2026)]
  • 02Although more extensive clinical research is needed to determine their long-term efficacy and safety, the evidence now available indicates that phytochemicals may be beneficial supplements to traditional cardiovascular treatments. [Alatawi K (2026)]
  • 03Cardiovascular diseases (CVDs) continue to be the world's leading cause of death and a major global healthcare burden. [Alatawi K (2026)]
  • 04Concerns about side effects and long-term therapy restrictions have raised interest in supplementary therapeutic approaches, even if traditional pharmaceutical and surgical procedures are still crucial to the management of CVD. [Alatawi K (2026)]
The current Migaku evidence database contains 3 reusable source documents for Plant Sterols Cholesterol Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts. - Evidence from published experimental, clinical, and mechanistic investigations that were indexed in PubMed, Scopus, Web of Science, and Google Scholar between 2014 and 2025 is compiled in this review. [Alatawi K (2026); evidence level 3] - Although more extensive clinical research is needed to determine their long-term efficacy and safety, the evidence now available indicates that phytochemicals may be beneficial supplements to traditional cardiovascular treatments. [Alatawi K (2026); evidence level 3] - Cardiovascular diseases (CVDs) continue to be the world's leading cause of death and a major global healthcare burden. [Alatawi K (2026); evidence level 3] - Concerns about side effects and long-term therapy restrictions have raised interest in supplementary therapeutic approaches, even if traditional pharmaceutical and surgical procedures are still crucial to the management of CVD. [Alatawi K (2026); evidence level 3] - Dyslipidemias, particularly those associated with an increase in the circulating burden of atherogenic apolipoprotein (Apo) B-containing lipoproteins, such as hypercholesterolemia (elevated total cholesterol and low-density lipoprotein cholesterol [LDL-C]), hypertriglyceridemia (elevated triglycerides [TG]), and mixed dyslipidemia (elevated LDL-C and TG), are well-established ASCVD risk factors [,,]. [Maki Kevin C. (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Therapeutic potential of phytochemical compounds in cardiovascular disease: a comprehensive review.
  2. Effects of Dietary Protein Quantity, Source, and Type on Plasma Lipids and Lipoproteins and Their Roles in Dyslipidemia Management in Humans
  3. Genetic Influence on LDL-Cholesterol Levels: Role of Polygenic Risk Scores and Lp(a) Beyond Monogenic Hypercholesterolemia